Natera gains Japan approval for Signatera colorectal test
Share
Natera (NASDAQ:NTRA) said its Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for use in colorectal cancer in the adjuvant setting.
